N-PEP-12 is a derivative of
cerebrolysin, a brain-derived
neuropeptide compound that has been approved for the treatment of
Alzheimer's disease (AD) in more than 30 countries.
N-PEP-12 is much less potent than
cerebrolysin but it can be administered orally whereas the parent compound must be administered through multiple
intravenous infusions. This study was undertaken to determine whether
N-PEP-12 is effective in improving memory and other cognitive abilities among healthy older adults who have experienced 'normal' age-related
memory loss. Subjects were 54 males and females, aged 50 years and older, who presented both subjective and objective evidence of
memory loss since early adulthood. The study was a fully randomized, double-blind comparison of
N-PEP-12 and placebo. Cognitive assessments were performed at baseline and following 30 days of treatment. The primary outcome measure was the
Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) Memory score, with the Syndrom Kurz Test (SKT) test, digit cancellation, digit span, verbal fluency and clinical ratings as secondary outcomes.
N-PEP-12 treated subjects performed better than placebo-treated subjects on the ADAS-cog Memory score, the SKT, clinical ratings and some, but not other tests.
N-PEP-12 may be an effective treatment for
memory loss in healthy older adults.